Table 2 Factors associated with successful transition to the 3-month dosing interval in patients treated with canakinumab

Abdominal pain n (%)

29 (100)

7 (100)

n/a

Arthritis n (%)

15 (51.7)

3 (42.9)

1.00 ^f

Chest pain n (%)

8 (27.6)

4 (57.1)

0.190 ^f

Pericarditis n (%)

3 (10.3)

0

1.00 ^f

Fever n (%)

29 (100)

7 (100)

n/a

Erysipelas-like erythema n (%)

6 (20.7)

2 (28.6)

0.639 ^f

Protracted febrile myalgia n (%)

2 (6.9)

1 (14.3)

0.488 ^f

Anakinra use prior to canakinumab n (%)

11 (37.9)

5 (71.4)

0.204 ^f

Anemia n (%)

9 (31.0)

4 (57.1)

0.225 ^f

Splenomegaly n (%)

3 (10.3)

3 (42.9)

0.073 ^f

Age at diagnosis (years) median (min-max)

3.5 (0.92-14.0)

3 (1.92–9.67)

0.549

Number of attacks in the last 6 months median (min-max)

6 (2–24)

5 (3–24)

0.762

Duration of attacks in the last 6 months (day) median (min-max)

3 (2–5)

3 (2–5)

0.902

AIDAI score of the last month before biologic treatment median (min-max)

18 (2–40)

16 (2–40)

0.564

WBC count (cells/µl) median (min-max)

9500 (4600–18,000)

10,760 (6100–15,510)

0.766

Hemoglobin (g/dl) median (min-max)

12.0 (10.3–14.6)

11.0 (8.9–13.2)

0.166

Platelet count (10³ cells/µl) median (min-max)

298 (145–620)

317 (190–653)

0.655

ESR (mm/h) median (min-max))

27 (4–63)

22 (8–88)

0.609

SAA (mg/L) median (min-max)

71.5 (1.0-970.0)

55.0 (13.0-191.0)

0.877

CRP (mg/L) median (min-max)

42.0 (0.2–346.0)

56 (18–214)

0.418

Duration of anakinra use prior to canakinumab(months) median (min-max)

4.0 (1–23)

3.0 (1–6)

0.254

Colchicine treatment duration prior to canakinumab (months) median (min-max)

81.0 (4-192)

49.0 (6-125)

0.401